Costly Public Option Precursor Advances

The Connecticut General Assembly is exploring ways to address rising healthcare costs, including through controversial legislation designed to ultimately pave the way for a public option.

SB 3 creates a state‑run “CT Option” health program financed by the newly proposed Connecticut Affordable Health Care Trust Fund and adopts aggressive cost-containment strategies

The bill cleared the Human Services Committee on a 16-7 vote March 19 and now awaits action in the Senate.

The trust fund will rely on an initial $200 million transfer from the Federal Cuts Response Fund, but the bill goes much further.

It authorizes the use of additional state and federal dollars without clear limits or guardrails.  

This lack of defined financial parameters raises concerns from the business community over potential violations of the fiscal guardrails.  

Lack of Oversight

SB 3 also delegates broad authority to the Office of Policy and Management, which will be tasked with creating a working group to design and implement the CT Option.

While the group includes state officials and legislative leaders, it is not required to include commercial insurers, employers, or small business representatives.  

Even more concerning, the bill requires only one public hearing before implementing the working group’s model.   

By shifting key decisions to an administrative working group with minimal public input, the bill effectively sidelines the legislature’s traditional role in shaping major healthcare policy.

“The CT Option could become an expensive and ineffective experiment—one that Connecticut’s employers ultimately pay for.”

CBIA’s Grace Brangwynne

This means less transparency, less accountability, and fewer opportunities to influence decisions that directly affect healthcare costs.  

The CT Option will also rely on subsidies that will  likely be financed through assessments on insurers and providers—costs that will inevitably be shifted onto those enrolled in private insurance.  

“For many small businesses already struggling with rapidly rising premiums, additional cost‑shifting would make coverage even less affordable and could drive further premium increases,” CBIA’s Grace Brangwynne said.

“Without meaningful guardrails or stakeholder involvement, the CT Option could become an expensive and ineffective experiment—one that Connecticut’s employers ultimately pay for.”

Affordability, Sustainability

Connecticut’s long-term economic health depends on a system that is affordable for patients, and sustainable for employers.

As the state works to reduce costs and improve access, policy decisions must also support an environment where businesses can invest, grow, and create jobs—especially in high-value sectors like bioscience and advanced technology. 

In practice, SB 3 extends Medicaid-like reimbursement levels and mandatory rebate structures into the commercial market. 

Instead of lowering overall healthcare spending, price control frameworks often shift costs onto commercially insured families.

This shift functions as a price control model, which has historically produced unintended consequences that go far beyond the business community.

Instead of lowering overall healthcare spending, price control frameworks often shift costs onto commercially insured families—groups already facing some of the highest premiums.

These models also rely on restrictive tools such as narrow formularies, prior authorization, and step therapy, which can delay or limit access to advanced therapies.

Cost Drivers

Over time, these pressures weaken commercial risk pools, reduce plan flexibility, and contribute to higher premiums.

They also limit the resources available for research and development across the life sciences sector.

A stable commercial market is essential to earlystage discovery, clinical trials, and the development of nextgeneration treatments.

Achieving real healthcare savings requires examining the full cost picture.

When reimbursement falls below sustainable levels, the innovation pipeline slows, affecting how quickly new therapies reach patients, particularly those with rare or complex conditions.  

Achieving real healthcare savings requires examining the full cost picture, including hospital care, procedures, imaging, routine visits, home health services, and how insurance plans are structured.

It is critical to consider how policy design affects market stability, patient access, and the state’s ability to remain a competitive hub for bioscience innovation and business growth. 

---

For more information, contact CBIA’s Grace Brangwynne (860.244.1163) or Jenna Grasso (860.244.1169).